€8.34 -0.5 -5.2%
Last Trade - 4:35pm
| Market Cap | ÂŁ141.0m |
| Enterprise Value | ÂŁ131.0m |
| Revenue | ÂŁ1.00m |
| Position in Universe | 468th / 846 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 1.68 | 1.49 | 1.30 | 1.03 | 0.97 | 1.00 | 1.27 | -12.9% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | October 1, 2018 |
| Public Since | February 1, 2018 |
| No. of Shareholders: | n/a |
| No. of Employees: | 45 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Euronext - Brussels |
| Shares in Issue | 18,438,435 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Technologiepark 122 Zwijnaarde, GENT, 9052, Belgium |
| Web | https://www.sequanamedical.com/ |
| Phone | +32 9 2928065 |
| Contact | () |
| Auditors | PricewaterhouseCoopers Bedijfsrevisoren |
As of 4:35pm, shares in Sequana Medical NV are trading at €8.34, giving the company a market capitalisation of £141.0m. This share price information is delayed by 15 minutes.
Shares in Sequana Medical NV are currently trading at €8.34 and the price has moved by 33.33% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sequana Medical NV price has moved by 27.44% over the past year.
Of the analysts with advisory recommendations for Sequana Medical NV, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sequana Medical NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sequana Medical NV is scheduled to issue upcoming financial results on the following dates:
Sequana Medical NV does not currently pay a dividend.
Sequana Medical NV does not currently pay a dividend.
Sequana Medical NV does not currently pay a dividend.
To buy shares in Sequana Medical NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Sequana Medical NV are currently trading at €8.34, giving the company a market capitalisation of £141.0m.
Here are the trading details for Sequana Medical NV:
Based on an overall assessment of its quality, value and momentum, Sequana Medical NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Sequana Medical NV are currently priced at €8.34. At that level they are trading at 52.27% discount to the analyst consensus target price of 0.00.
Analysts covering Sequana Medical NV currently have a consensus Earnings Per Share (EPS) forecast of -1.33 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sequana Medical NV. Over the past six months, the relative strength of its shares against the market has been 26.72%. At the current price of €8.34, shares in Sequana Medical NV are trading at 22.43% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Sequana Medical NV.
Sequana Medical NV's management team is headed by:
Here are the top five shareholders of Sequana Medical NV based on the size of their shareholding:
